Questcor Pharmaceuticals (QCOR) Collapses Ahead of Negative Report
Tweet
Share
E-mail
Get Alerts QCOR Hot Sheet
Join SI Premium – FREE
Shares of Questcor Pharmaceuticals (Nasdaq: QCOR) collapsed mid-day Wednesday after TheStreetSweeper.org indicated that a negative report on the company is forthcoming.
The stock dropped 7.2 percent to $38.54 at last check.
In an e-mail message to members, TheStreetSweeper.org said, "The first story in a detailed two-part series on Questcor Pharmaceuticals (Nasdaq: QCOR) will be released early next week, with the second installment scheduled to appear soon after that."
The group said the first article raises serious questions about the aggressive marketing practices of the company. The second story will focus on business practices with a "hard look" at the leaders of the company.
TheStreetSweeper has sold 80,599 shares of QCOR short at an average price of $41.46, they said.
The stock dropped 7.2 percent to $38.54 at last check.
In an e-mail message to members, TheStreetSweeper.org said, "The first story in a detailed two-part series on Questcor Pharmaceuticals (Nasdaq: QCOR) will be released early next week, with the second installment scheduled to appear soon after that."
The group said the first article raises serious questions about the aggressive marketing practices of the company. The second story will focus on business practices with a "hard look" at the leaders of the company.
TheStreetSweeper has sold 80,599 shares of QCOR short at an average price of $41.46, they said.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Humana (HUM) surges on Q1 beat, reiterated adjusted earnings outlook
- Tesla (TSLA) soars on Q1 print
- Senate Committee Investigates Ozempic and Wegovy Costs - NYT
Create E-mail Alert Related Categories
Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
